JP2013507377A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013507377A5 JP2013507377A5 JP2012533303A JP2012533303A JP2013507377A5 JP 2013507377 A5 JP2013507377 A5 JP 2013507377A5 JP 2012533303 A JP2012533303 A JP 2012533303A JP 2012533303 A JP2012533303 A JP 2012533303A JP 2013507377 A5 JP2013507377 A5 JP 2013507377A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- chemokine
- activity
- pharmaceutically acceptable
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 102000009410 Chemokine receptor Human genes 0.000 claims 4
- 108050000299 Chemokine receptor Proteins 0.000 claims 4
- 102000019034 Chemokines Human genes 0.000 claims 4
- 108010012236 Chemokines Proteins 0.000 claims 4
- 206010065040 AIDS dementia complex Diseases 0.000 claims 2
- 206010001889 Alveolitis Diseases 0.000 claims 2
- 206010002329 Aneurysm Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 claims 2
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 claims 2
- 102000004500 CCR1 Receptors Human genes 0.000 claims 2
- 108010017319 CCR1 Receptors Proteins 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000003589 nefrotoxic effect Effects 0.000 claims 2
- 201000008383 nephritis Diseases 0.000 claims 2
- 231100000381 nephrotoxic Toxicity 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24927009P | 2009-10-07 | 2009-10-07 | |
| US61/249,270 | 2009-10-07 | ||
| PCT/US2010/051731 WO2011044309A1 (en) | 2009-10-07 | 2010-10-07 | Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013507377A JP2013507377A (ja) | 2013-03-04 |
| JP2013507377A5 true JP2013507377A5 (enExample) | 2013-11-21 |
| JP5788397B2 JP5788397B2 (ja) | 2015-09-30 |
Family
ID=43334406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012533303A Expired - Fee Related JP5788397B2 (ja) | 2009-10-07 | 2010-10-07 | ケモカイン受容体活性の調節薬としてのピペリジニル誘導体のプロドラッグ |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8410139B2 (enExample) |
| EP (1) | EP2486013B1 (enExample) |
| JP (1) | JP5788397B2 (enExample) |
| KR (1) | KR20120083900A (enExample) |
| CN (1) | CN102648179B (enExample) |
| AR (1) | AR078543A1 (enExample) |
| AU (1) | AU2010303441A1 (enExample) |
| BR (1) | BR112012007755A2 (enExample) |
| CA (1) | CA2777032A1 (enExample) |
| CL (1) | CL2012000882A1 (enExample) |
| CO (1) | CO6440510A2 (enExample) |
| EA (1) | EA022150B1 (enExample) |
| IL (1) | IL219122A (enExample) |
| MX (1) | MX2012003656A (enExample) |
| NZ (1) | NZ599261A (enExample) |
| PE (1) | PE20121109A1 (enExample) |
| TW (1) | TW201118070A (enExample) |
| WO (1) | WO2011044309A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201607907PA (en) * | 2014-04-08 | 2016-10-28 | Neurovive Pharmaceutical Ab | Novel cell-permeable succinate compounds |
| EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) * | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| EP3589287B1 (en) | 2017-03-01 | 2022-09-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
| CN110776481B (zh) * | 2018-07-24 | 2023-06-16 | 四川大学华西医院 | 一类双阳离子化合物及其制备方法和用途 |
| CN108727248B (zh) * | 2018-07-25 | 2021-05-25 | 四川大学华西医院 | 一类双季铵化合物及其制备方法和用途 |
| CA3123583A1 (en) | 2018-12-17 | 2020-06-25 | Achillion Pharmaceuticals, Inc. | Targeted dosing for the treatment of complement mediated disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6444686B1 (en) * | 1998-12-18 | 2002-09-03 | Brsitol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| WO2004082682A1 (en) * | 2003-03-18 | 2004-09-30 | Merck & Co. Inc. | Amino cyclobutylamide modulators of chemokine receptor activity |
| US7601844B2 (en) * | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| AU2007275931B2 (en) * | 2006-07-19 | 2011-06-16 | Astrazeneca Ab | Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity |
| EP2173714B9 (en) | 2007-07-24 | 2013-04-10 | Bristol-Myers Squibb Company | Piperidine derivatives as modulators of chemokine receptor activity |
| EP2173713B1 (en) | 2007-07-24 | 2016-02-17 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| TWI433838B (zh) * | 2008-06-25 | 2014-04-11 | 必治妥美雅史谷比公司 | 作為趨化因子受體活性調節劑之六氫吡啶衍生物 |
-
2010
- 2010-10-04 US US12/896,955 patent/US8410139B2/en active Active
- 2010-10-06 TW TW099134093A patent/TW201118070A/zh unknown
- 2010-10-06 AR ARP100103636A patent/AR078543A1/es unknown
- 2010-10-07 CA CA2777032A patent/CA2777032A1/en not_active Abandoned
- 2010-10-07 AU AU2010303441A patent/AU2010303441A1/en not_active Abandoned
- 2010-10-07 MX MX2012003656A patent/MX2012003656A/es active IP Right Grant
- 2010-10-07 PE PE2012000437A patent/PE20121109A1/es not_active Application Discontinuation
- 2010-10-07 EA EA201270468A patent/EA022150B1/ru not_active IP Right Cessation
- 2010-10-07 BR BR112012007755A patent/BR112012007755A2/pt not_active IP Right Cessation
- 2010-10-07 JP JP2012533303A patent/JP5788397B2/ja not_active Expired - Fee Related
- 2010-10-07 WO PCT/US2010/051731 patent/WO2011044309A1/en not_active Ceased
- 2010-10-07 NZ NZ599261A patent/NZ599261A/xx not_active IP Right Cessation
- 2010-10-07 CN CN201080055421.4A patent/CN102648179B/zh not_active Expired - Fee Related
- 2010-10-07 KR KR1020127011586A patent/KR20120083900A/ko not_active Withdrawn
- 2010-10-07 EP EP10766190.2A patent/EP2486013B1/en not_active Not-in-force
-
2012
- 2012-03-29 CO CO12053565A patent/CO6440510A2/es active IP Right Grant
- 2012-04-05 CL CL2012000882A patent/CL2012000882A1/es unknown
- 2012-04-05 IL IL219122A patent/IL219122A/en not_active IP Right Cessation
-
2013
- 2013-03-05 US US13/785,039 patent/US20130178444A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013507377A5 (enExample) | ||
| PH12020552187A1 (en) | Pcsk9 antagonist compounds | |
| JP2011528658A5 (enExample) | ||
| EP3363797A8 (en) | Oral dosage form of apoptosis signal-regulating kinase inhibitors | |
| JP2017512186A5 (enExample) | ||
| WO2006124490A3 (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
| RU2018142605A (ru) | Селективный ингибитор фосфатидилинозитол-3-киназы-гамма | |
| IN2012CH01573A (enExample) | ||
| JP2017533968A5 (enExample) | ||
| JP2012532112A5 (enExample) | ||
| JP2016520618A5 (enExample) | ||
| JP2016525136A5 (enExample) | ||
| MX2021011472A (es) | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. | |
| JP2016531113A5 (enExample) | ||
| JP2019516739A5 (enExample) | ||
| JP2017514910A5 (enExample) | ||
| JP2016540749A5 (enExample) | ||
| JP2017524735A5 (enExample) | ||
| JP2014114295A5 (enExample) | ||
| JP2016535031A5 (enExample) | ||
| JP2016512227A5 (enExample) | ||
| JP2016509051A5 (enExample) | ||
| JP2016510326A5 (enExample) | ||
| JP2012502111A5 (enExample) | ||
| JP2015529681A5 (enExample) |